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Abstract
Lymphoma in HIV-infected patients is AIDS defining. This is the second most common AIDS defining malignancy
after Kaposi’s sarcoma. Development of lymphoma in HIV patients is related to immunosuppression and high viral
load. Co-infection with other lymphotrophic viruses especially EBV is also strongly associated with development of
lymphoma in HIV patients. Despite advances in HAART therapy, incidence of diffuse large B cell lymphoma in HIV-
infected patients remains significantly higher than in the general population.
Early diagnosis is challenging due to presence of opportunistic infections and atypical presentation of the
lymphoma in this subset of patients. Atypical imaging findings are not unusual, and the diagnosis of lymphoma on
imaging is on many occasions unexpected as the patient would ideally be initially investigated for presumed
opportunistic infection.
Lymphoma treatment approaches in HIV patients are complicated by comorbidity with opportunistic infections and
performance status of the patients. Treatment failure and early relapse are also common in AIDS-related lymphoma.
This review article highlights the common and unusual multimodality imaging findings in HIV-associated
lymphoma.
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Teaching points
 Non-Hodgkin lymphoma is the second most
common malignancy in HIV patients.
 AIDS-related NHL is an aggressive multisystem
disease with a poor prognosis.
 CT and FDG PET CT imaging are crucial in initial
diagnosis, staging, and follow-up of AIDS-related
lymphoma.
 Knowledge of imaging features of diffuse features of
HIV-associated lymphoma can help to differentiate
lymphoma from infectious comorbidities which are
common in HIV/AIDS patients.
Introduction
HIV remains a critical health problem; as of 2018, 37.9
million people globally were living with HIV, of which
24.5 million had access to highly active antiretroviral
therapy (HAART) [1]. In 2018, approximately 770,000
people died from AIDS-related illnesses. This represents
a significant reduction by more than 56% since the peak
in 2004. UNAIDS estimates that approximately $26.2
billion will be required worldwide for the AIDS response
in 2020 [1]. As the lifespan of HIV-infected patients is
increasing, malignancies now contribute a significant
cause of morbidity and mortality in HIV-infected pa-
tients. Non-Hodgkin’s lymphoma is the second most
common HIV-related malignancy after Kaposi’s sarcoma
[2]. The other AIDS defining malignancy is invasive cer-
vical cancer [3].
Twenty-five to 40% of HIV-positive patients will de-
velop a malignancy; approximately 10% will be non-
Hodgkin’s lymphoma. Since implementation of ART, the
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risk of non-Hodgkin’s lymphoma initially declined, likely
related to improvement in CD4 counts [4, 5]. The risk of
developing lymphoma remains higher in those with low
CD4 counts and high HIV viral loads [6]. Approximately
75% of the non-Hodgkin’s lymphoma in HIV patients is
aggressive diffuse large B cell lymphoma (DLBCL). Indo-
lent lymphomas comprise less than 10% of HIV-related
lymphomas [2, 5].
The pathogenesis of non-Hodgkin’s lymphoma in HIV
is not well understood. Epstein-Barr virus is however
known to play an important role [7]. HIV lymphomas
are commonly derived from B cells. Immune dysregula-
tion also plays an important role, with progression of
lymphoma associated with interleukin 6 and interleukin
10 production. Genetic dysregulation is also a prominent
feature in AIDS-related diffuse large B cell lymphoma,
notably BCL 6 expression, and Myc overexpression.
BCL-2 activation is generally not seen in HIV-related
lymphoma.
Imaging in HIV and lymphoma
The imaging findings of NHLs are primarily masses and
lymphadenopathy [8, 9]. Extranodal DLBCL is common
in the setting of HIV. Most HIV-positive patients have
concomitant infectious disease, or are initially evaluated
for presumed infectious disease. Initial imaging prior to
diagnosis is guided by clinical presentation and index of
clinical suspicion.
The primary imaging modality is usually contrast-
enhanced CT. Besides the established imaging find-
ings of nodal enlargement in HIV negative patients,
other unusual findings are not uncommon in AIDS-
related lymphoma. These include necrosis of the in-
volved nodes, large extranodal soft tissue masses, and
bone destruction secondary to lymphoma involve-
ment. AIDS-related lymphoma also presents with
multi-organ involvement and bulky disease [10]. 18
FDG PET/CT is a useful tool in initial staging and re-
sponse assessment of lymphoma in both HIV-positive
and HIV-negative patients [11, 12]. The high-grade
HIV-associated DLBCLs are more likely to show avid
uptake of 18 F-FDG. It is also useful in assessment of
sites of FDG avid disease which may not be immedi-
ately apparent on conventional CT. PET CT is how-
ever inherently limited in tissues which show high
background FDG uptake such as the brain.
Fig. 1 Chest radiograph of a 19-year-old HIV-positive patient with low CD4 count. He presented with cough and dyspnea and was initially being
evaluated for possible atypical pneumonia. The chest radiograph showed multiple focal opacities predominantly in the lower lung zones. On CT,
there were lung parenchymal nodules/masses of variable sizes which were also intensely FDG avid on PET CT. There was extensive lymphoma
involvement elsewhere including in the liver, spleen (splenic activity higher than liver background), and multiple nodal sites above and below the
diaphragm. Biopsy of the liver lesion was consistent with DLBCL
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Lung findings
Pulmonary involvement of diffuse large B cell lymphoma
is usually a manifestation of systemic disease rather than
primary pulmonary lymphoma [13]. A few isolated case
reports of primary pulmonary lymphoma in the setting
of HIV have been described. Up to two-thirds of patients
present with respiratory symptoms of cough and dys-
pnea and would therefore be evaluated for an infective
process, initially with the chest radiograph and CT chest.
On imaging, pulmonary lymphoma can appear as an iso-
lated mass, multiple pulmonary nodules/masses, or dif-
fuse consolidative opacities [14] (Fig. 1). High-grade
pulmonary lymphoma in HIV is invariably 18 FDG avid.
Patients may also present with pleural effusion.
Gastrointestinal tract findings
Gastrointestinal tract is the most commonly affected
extranodal site in AIDS-related NHL and is usually
multifocal. The symptoms depend on the site of involve-
ment and range from abdominal pain, diarrhea weight
loss, gastrointestinal bleeding, or symptoms related to
perforation. In a small series of 48 patients, the stomach
and duodenum were the most commonly involved site.
Bowel involvement presents as soft tissue bowel thicken-
ing, typically with associated dilatation rather than nar-
rowing of the bowel lumen (Fig. 2), due to involvement
of the myenteric plexus [15]. There is usually associated
mesenteric lymphadenopathy. Some patients may also
present with ascites.
Liver and spleen
Liver and spleen involvement are not uncommon in
AIDS-related lymphoma. This can either be focal or dif-
fuse involvement, with hepatosplenomegaly and focal
masses on imaging. These appear as hypoattenuating
focal lesions which do not show any significant enhance-
ment on all phases. Additionally, the masses typically en-
case but do not invade the hepatic vasculature or biliary
tree [16]. Absence of significant arterial phase enhance-
ment, vessel penetration sign, and absence of vascular
thrombosis are useful clues in diagnosing lymphoma
[17] (Fig. 3). In severely immunocompromised lesions,
the hypoattenuating focal lesions may demonstrate ring
enhancement on contrast-enhanced CT and can easily
be confused with tuberculous or fungal microabscesses
(Figs. 3 and 4). FDG PET CT may demonstrate avid focal
deposits within these organs. In the absence of a focal le-
sion, diffusely increased FDG uptake within the spleen,
higher than the liver background, is considered diffuse in-
volvement of the spleen (Fig. 1). It should be noted that
diffuse splenic FDG uptake can also be reactive. This is es-
pecially important in patients on chemotherapy.
Other solid organs
HIV-associated lymphoma can rarely involve the kid-
neys, pancreas, and adrenal glands. The incidence of
pancreatic involvement has been reported to be up
to 5% in HIV patients [18]. The kidneys have no in-
trinsic lymphoid tissue, and their involvement
Fig. 2 Coronal reformats of a CECT abdomen and pelvis of a recently diagnosed HIV-positive patient who presented with abdominal pain,
diarrhea, and weight loss show long-segment bowel thickening involving the distal ileum and caecum (long arrow). There was also mesenteric
lymphadenopathy, with some necrotic nodes, (short slender arrow) and a moderate ascites (short fat arrow). There were also enlarged centrally
necrotic right inguinal lymph nodes
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therefore signifies disseminated disease [8]. On im-
aging, infiltrative masses tend to be hyperattenuating
to the renal parenchyma on the unenhanced CT
which can be a useful clue. Lymphomatous infiltra-
tion also commonly occurs along the renal capsule
and sinus [19] (Fig. 5).
Bone findings
Bone involvement occurs in approximately 5% of dissemi-
nated lymphoma cases although this may be higher in
HIV. Imaging appearances are nonspecific and range from
both mixed lytic and sclerotic lesions and extensive soft
tissue involvement [16, 17] (Fig. 6). Evaluation for soft tis-
sue involvement is critical as the isolated bone findings
may mimic osteomyelitis. Differential diagnoses also in-
clude Ewing’s sarcoma which could present with bone de-
struction and associated soft tissue component.
Role of imaging during treatment of HIV-associated
DLBCL
Despite advances in HAART and chemotherapy, HIV-
associated DLBCL carries a poor prognosis related to
Fig. 3 Axial CT images axial contrast-enhanced CT image and liver ultrasound of a patient with HIV-associated primary hepatic lymphoma. The contrast-
enhanced CT shows a homogeneous soft tissue attenuation mass which does not show significant enhancement, and with fear preservation of the
surrounding liver architecture. The mass displaces or encases the hepatic veins but does not invade vasculature or lead to tumor thrombus. On ultrasound, it
appears as a fairly homogenous mass hypoechoic to the liver parenchyma. There is no increase vascularity within the mass or in its periphery
Fig. 4 Coronal and axial CECT images of the abdomen (a and b) show hepatomegaly and a heterogenous hypoattenuating mass infiltrating
through most of the right lobe of the liver. The infiltrative liver mass had more focal hypoattenuating areas (fat arrow). Aortocaval lymph nodes
are also noted (short arrow). Axial CT through the pelvis in bone window (c) shows a permeative process involving the left femoral head and
neck and associated pathological fracture
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the HIV disease and aggressive nature of the lymphoma.
The standard therapy is CHOP chemotherapy regimen,
with or without rituximab (R-CHOP). Previous studies
before rituximab recorded complete response rates of
30–50% and 2-year survival rates of less than 20% [23].
Although rituximab has revolutionized the treatment of
CD20-positive lymphomas in the HIV-negative popula-
tion, its role in HIV-related lymphoma is not as clearly
defined, given the profound cellular and humoral im-
munodeficiency that this agent can cause [24]. Many au-
thors suggest the addition of rituximab to the treatment
regimen if the CD4 count is over 50/mL and individual-
ized consideration for patients with CD4 less than 50
[25]. Imaging is crucial in assessing response to treat-
ment. An interim PET/CT is useful in assessment of
treatment response.
Posttreatment surveillance
Current evidence shows no clinical benefit of surveil-
lance imaging [20, 21], although this is routinely offered
to patients in an effort to detect recurrence before the
onset of clinical symptoms when patients are more likely
to accrue maximal benefit from salvage treatment. In the
clinical setting, most patients are evaluated with CT dur-
ing surveillance. Imaging with PET CT is not recom-
mended for posttreatment surveillance due to high false
positive rates. The false positive rates could even be
higher in HIV patients due to some opportunistic
Fig. 5 Ultrasound image of the left kidney in a HIV-positive male demonstrates heterogeneously echogenic areas in the medulla extending to
the collecting system. Unenhanced CT KUB showed diffuse thickening of the renal pelvis with hyperdense soft tissue material relative to the renal
parenchyma. Heterogenous infiltration of the kidney is seen on the postcontrast CT images in arterial and urographic phases
Fig. 6 CECT of the pelvis in soft tissue window (a) and bone window
(b). A mixed lytic and sclerotic process involving the sacrum and
extending to the iliac bones through the sacroiliac joints is seen. There
are associated pathological fractures and a large extra osseous soft
tissue component. There are also enlarged necrotic bilateral pelvic
sidewall and inguinal lymph nodes
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infections which may have presentation similar to that
of lymphoma. Disease recurrence is higher in HIV-
positive patients than HIV negative patients. This may
be attributable to initial bulk disease, persistent immune
dysregulation, and suboptimal treatment in this subset
of patients. Recurrence can either be at the site of pri-
mary disease or in distant sites. Imaging strategy should
therefore be guided by clinical presentation and the de-
gree of clinical suspicion (Figs. 7, 8, 9, and 10).
Conclusion
Imaging is valuable for diagnosis and differential diagno-
sis of AIDS-related lymphomas and facilitates staging
and monitoring of therapeutic effects. However, there
can be atypical imaging features of AIDS-related DLBCL
compared to findings in HIV-negative patients. Know-
ledge of these atypical imaging features may facilitate the
diagnosis of lymphoma over infectious disease in the set-
ting of HIV/AIDS.
Fig. 7 A 46-year-old female patient who had pancreatic lymphoma (a) had a negative PET CT at the end of treatment (b and c). Nine months
later, there was local disease recurrence at the pancreatic head on follow-up FDG PET CT scan (d and e)
Fig. 8 Newly diagnosed HIV-positive patient who had CD4 count of 151 presented with primary gastric lymphoma. He was treated with R-CHOP
regimen complicated by severe neutropenic sepsis. Intrathecal chemotherapy was deferred to cycle 3 due to poor performance. Interim PET/CT
showed good treatment response of the gastric tumor but there was refractory neuraxial disease seen as FDG avid conus medullaris
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Fig. 9 This patient with extensive retroperitoneal and renal disease (a and b) showed excellent response to treatment in the interim PET CT (c, d,
and e) after two cycles of R-CHOP. There was however early relapse with bulky disease developing in the retroperitoneum and the scrotum (f)
Fig. 10 Axial CT image (a) demonstrates bilateral axillary lymphadenopathy, proven to be DLBCL after biopsy. The patient successfully completed
treatment but developed CNS symptoms 1 year later. MRI of the brain (b) showed a large heterogenous mass in the left cerebral hemisphere
which biopsy was proven to be lymphoma. A previous MRI brain (c) was negative for CNS involvement
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